Investigator

Takashi Murakami

Professor · Shiga University of Medical Science, Obstetrics and Gynecology

TMTakashi Murakami
Papers(5)
mTOR inhibitors poten…Balancing Fertility P…MRI findings characte…Ovarian Leydig cell t…Comparison of postope…
Collaborators(10)
Tsukuru AmanoShunichiro TsujiAkiko NakamuraAkimasa TakahashiFuminori KimuraYuji TanakaMari DeguchiMasaya UnoMegumi AkiRyusuke Murakami
Institutions(6)
Shiga University Of M…Shiga UniversityNara Medical Universi…National Cancer Cente…Unknown InstitutionKyoto University Hosp…

Papers

Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer

To identify a relatively high-risk population in postoperative intermediate-risk cervical cancer and evaluate the effect of platinum-based adjuvant chemotherapy (CT). We retrospectively reviewed the medical records of patients with stage IA2-IIA cervical cancer who had been treated with radical hysterectomy and pelvic lymphadenectomy and classified as the intermediate-risk group for recurrence by postoperative pathological examination from January 2007 to December 2018 at 3 medical centers in Japan. First, patients with intermediate-risk were stratified by histological type and the number of intermediate-risk factors (IRF; large tumor diameter, lymph vascular space invasion, and deep cervical stromal invasion) and then divided into 2 groups: high and low-risk population (estimated 5-year recurrence-free survival [RFS] rate with no further therapy [NFT] <90% and ≥90%, respectively). Second, the efficacy of CT for the high-risk population was evaluated by comparing RFS and overall survival (OS) between the patients receiving CT and those with NFT. In total, 133 patients were included in the analysis. Among patients with squamous cell carcinoma (SCC) with all IRF or those with non-SCC with 2 to 3 IRF, the 5-year estimated RFS was <90% when treated with NFT. In this population, adjuvant CT was significantly superior to NFT regarding RFS (log-rank, p=0.014), although there was no statistical difference in OS. Patients with SCC with all 3 IRFs and those with non-SCC with 2 to 3 IRFs were at high risk for recurrence. Adjuvant CT is a valid treatment option for these populations.

25Works
5Papers
17Collaborators
Ovarian NeoplasmsBreast NeoplasmsApoptosisEndometriosisHematologic NeoplasmsGraft vs Host DiseaseUterine Cervical Neoplasms

Positions

2008–

Professor

Shiga University of Medical Science · Obstetrics and Gynecology

Education

1986

M.D.

Tohoku University